KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting - Seite 2
The second oral presentation, “Analysis of Growth Velocity in Children Treated for up to 12 Months with KP415, an Investigational ADHD Product Containing the Prodrug Serdexmethylphenidate (SDX),” provides an analysis of the potential effects of KP415 on expected gains in weight and height in children treated for up to 12 months. To be presented by Ann Childress, M.D., President of the Center for Psychiatry and Behavioral Medicine, the research examined the body weight and height of children who participated in a Phase 3, long-term, open label safety study of KP415, concluding that, consistent with prior studies of MPH products, long-term treatment with KP415 can lead to modest reductions in expected weight and lower-than-expected increases in height based on individual subject age and sex. However, such deficits relative to children in the general U.S. population diminish or plateau later in treatment.
In addition, a poster presentation titled, “Patterns of Abuse of Prescription Stimulant Products from the National Addictions Vigilance Intervention Program (NAVIPPRO): 2010-2018,” will highlight a study designed to characterize patterns of abuse of prescription stimulants, including MPH products, abuse among adolescents and adults being evaluated for substance abuse treatment. Submitted by Andrew Barrett, Ph.D., KemPharm’s Vice President, Scientific Affairs, data from the study suggests that abuse of prescription MPH products by multiple routes of administration remains prevalent in adolescents and adults and is associated with risky abuse-related behaviors such as injection drug use.
KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm’s co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.